Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389933 | 0.80 | — | — | |
| SCHEMBL11259385 | 0.79 | KCNA3 (0.37) | — | |
| SCHEMBL4620512 | 0.79 | — | — | |
| SCHEMBL3391990 | 0.79 | — | — | |
| SCHEMBL301735 | 0.78 | — | — | |
| SCHEMBL11884347 | 0.76 | — | — | |
| SCHEMBL248360 | 0.76 | — | — | |
| SCHEMBL11407846 | 0.76 | — | — | |
| SCHEMBL7666136 | 0.76 | MEN1 (0.30) | — | |
| SCHEMBL3850139 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | disclosed |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-8362264-B2 | Tryptophan antagonist; anticancer agents | DENDREON CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| EP-1663962-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1663962-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | DENDREON CORPORATION (US) | 2005-03-10 | — | — | US | disclosed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1201635-B1 | Process for producing 3-l-menthoxypropane-1,2-diol | TAKASAGO PERFUMERY CO LTD (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20020156327-A1 | Method for producing 3-l-menthoxypropane-1,2-diol | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6407293-B1 | ADDING L-MENTHOL TO A 1,2- EPOXY-3-HALOGENOPROPANE IN SOLVENT IN PRESENCE OF LEWIS ACID TO PRODUCE 1-HALOGENO-3-L-MENTHOXYPROPAN-2-OL; EPOXIDATING WITH BASE IN PRESENCE OF PHASE TRANSFER CATALYST; HYDROLYSIS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-0080148-B1 | 3-L-MENTHOXYPROPANE-1,2-DIOL | Takasago Perfumery Co., Ltd. (JP) | 1985-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156327-A1 | Method for producing 3-l-menthoxypropane-1,2-diol | LOXL2, FAAH2, LOXL1 | EPHX2 105/4885 |
| US-20130190296-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | EPHX2 3913/4885 |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | EPHX2 3488/4885 |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | EPHX2 4021/4885 |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | TRPC4, TRPC3, TRPC1 | EPHX2 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.